Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies

European Journal of Cancer

Volumn 49, Issue 15, 2013, Pages 3169-3175

  Matrana, M R ^a   Duran, C ^a   Shetty, A ^b   Xiao, L ^a   Atkinson, B J ^a   Corn, P ^a   Pagliaro, L C ^a   Millikan, R E ^c   Charnsangave, C ^a   Jonasch, E ^a   Tannir, N M ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c Essential Health   (United States)

Author keywords

Angiogenesis; Mammalian target of rapamycin; Metastatic renal cell carcinoma; Pazopanib; Targeted therapy; Tyrosine kinase inhibitor

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; CAPECITABINE; CEDIRANIB; ERLOTINIB; EVEROLIMUS; GEMCITABINE; INTERLEUKIN 2; LINIFANIB; PAZOPANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ARTICLE; CANCER MORTALITY; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; FATIGUE; FEMALE; HAIR; HAND FOOT SYNDROME; HUMAN; HYPERNATREMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOTHYROIDISM; KIDNEY CARCINOMA; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; METASTATIC CLEAR CELL RENAL CELL CARCINOMA; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN;

ANGIOGENESIS; MAMMALIAN TARGET OF RAPAMYCIN; METASTATIC RENAL CELL CARCINOMA; PAZOPANIB; TARGETED THERAPY; TYROSINE KINASE INHIBITOR;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RETROSPECTIVE STUDIES; SULFONAMIDES;

EID: 84884902024     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.06.003     Document Type: Article

References (33)

1. R.J. Motzer, M. Mazumdar, J. Bacik, W. Berg, A. Amsterdam, and J. Ferrara Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma J Clin Oncol 17 8 1999 2530 2540
2. T.M. Mekhail, R.M. Abou-Jawde, and G. Boumerhi Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma J Clin Oncol 23 4 2005 832 841
3. A.L. Alt, S.A. Boorjian, C.M. Lohse, B.A. Costello, B.C. Leibovich, and M.L. Blute Survival after complete surgical resection of multiple metastases from renal cell carcinoma Cancer 117 13 2011 2873 2882
4. T. Buchler, T. Pavlik, and Z. Bortlicek Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma Med Oncol 29 5 2012 3321 3324
5. M.R. Matrana, B. Atkinson, E. Jonasch, and N.M. Tannir Emerging targeted therapies in metastatic renal cell carcinoma Curr Clin Pharmacol 6 3 2011 189 198
6. C.N. Sternberg, I.D. Davis, and J. Mardiak Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 6 2010 1061 1068
7. R.J. Motzer, J. Bacik, and L.H. Schwartz Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma J Clin Oncol 22 3 2004 454 463
8. Motzer RJ, Hutson TE, Reeves J, et al. Randomized open-label phase III trial of pazopanib versus sunitinib in first-line treatment of patients with metastatic renal cell carcinoma (MRCC): results of the COMPARZ trial. 2012 ESMO Congress. Abstract LBA8. Presented October 1, 2012.
9. Escudier B, Porta C, Petri B, et al. Patient preference between pazopanib (Paz) and sunitinib: results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC) - PISCES study, NCT 01064310. 2012 ASCO Annual Meeting. Abstract CRA4502. Presented June 2, 2012.
10. R.J. Motzer, B. Escudier, and S. Oudard Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 9637 2008 449 456
11. B.I. Rini, B. Escudier, and P. Tomczak Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial Lancet 378 9807 2011 1931 1939
12. M. Matrana, B. Atkinson, and N. Tannir Combinatorial and sequential targeted therapy in metastatic renal cell carcinoma P. Lara, E. Jonasch, Kidney cancer 2012 Springer-Verlag 225 240
13. G. Hudes, M. Carducci, and P. Tomczak Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 22 2007 2271 2281
14. R. Dienstmann, I. Brana, J. Rodon, and J. Tabernero Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs Oncologist 16 12 2011 1729 1740
15. E.S. Robinson, E.V. Khankin, S.A. Karumanchi, and B.D. Humphreys Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker Semin Nephrol 30 6 2010 591 601
16. B.I. Rini, D.P. Cohen, and D.R. Lu Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib J Natl Cancer Inst 103 9 2011 763 773
17. Rini BI, Cohen DP, Lu D, et al. Hypertension (HTN) as a biomarker of efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib. GU ASCO 2010. Abstract 312.
18. J. Manola, P. Royston, and P. Elson Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group Clin Cancer Res 17 16 2011 5443 5450
19. B. Albouy, B. Billemont, and C. Massard Pancreatic metastasis from renal cell carcinoma: presentation, recurrence, survival, and response to antiangiogenic therapy J Clin Oncol 27 Suppl. 2009 Abstract e16137
20. M. D'Ambra, C. Ricci, R. Casadei, and F. Minni Pancreatic metastasis from renal cell carcinoma Urologia 78 Suppl. 18 2011 5 8
21. N.M. Tannir, Y.N. Wong, and C.K. Kollmannsberger Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure Eur J Cancer 47 18 2011 2706 2714
22. G. Di Lorenzo, G. Carteni, and R. Autorino Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer J Clin Oncol 27 27 2009 4469 4474
23. J.A. Garcia, T.E. Hutson, and P. Elson Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab Cancer 116 23 2010 5383 5390
24. K. Zimmermann, A. Schmittel, and U. Steiner Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib Oncology 76 5 2009 350 354
25. J. Sepulveda, P. Maroto, and R. Andres Sorafenib as a second-line and sequential therapy for patients with metastatic renal cell carcinoma (mRCC): analysis for safety and activity on sunitinib progressive pts J Clin Oncol 26 Suppl. 2008 Abstract 16100
26. C. Porta, G. Procopio, and G. Carteni Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases BJU Int 108 8, Pt. 2 2011 E250 E257
27. E. Herrmann, N. Marschner, and M.O. Grimm Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma World J Urol 29 3 2011 361 366
28. M.P. Sablin, S. Negrier, and A. Ravaud Sequential sorafenib and sunitinib for renal cell carcinoma J Urol 182 1 2009 29 34 discussion
29. A.Z. Dudek, J. Zolnierek, A. Dham, B.R. Lindgren, and C. Szczylik Sequential therapy with sorafenib and sunitinib in renal cell carcinoma Cancer 115 1 2009 61 67
30. T.K. Choueiri, A.J. Brick, and D. McDermott Treatment and dosing patterns for angiogenesis inhibitor (AIS) therapies in patients with metastatic renal cell carcinoma (MRCC) Ann Oncol 19 Suppl. 8 2008 viii191 viii192
31. C. Eichelberg, R. Heuer, and F.K. Chun Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis Eur Urol 54 6 2008 1373 1378
32. G. Di Lorenzo, C. Buonerba, and P. Federico Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma Eur Urol 58 6 2010 906 911
33. K. Park, J.L. Lee, and I. Park Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI Med Oncol 29 5 2012 3291 3297